A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA

ConditionsMultiple System Atrophy (MSA)Parkinson's Disease (PD)

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age40+

SponsorSynusight Biotech (Shanghai) Co., Ltd.

About this trial

The non-randomized, open-label phase I study aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and pharmacokinetics of SST001 in healthy volunteers, patients with MSA and patients with PD.

Eligibility criteria

Qualifiers

Sign the informed consent form approved by IEC.

Male or female participants aged ≥40 years old.

Adequate organ functions.

Proper contraception methods.

Disqualifiers

Being pregnant or lactating.

History of other severe neurological disorders.

History of serious or uncontrolled medical condition.

Active HBV/HCV/HIV infection, etc.

Trial design

Treatments tested in this trial

SST001

Treatment groups

30 Participants

are divided into 1 treatment group

Sponsors and collaborators

Synusight Biotech (Shanghai) Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov